Status:
NOT_YET_RECRUITING
Photobiomodulation in Radiodermatitis in People With Breast Cancer
Lead Sponsor:
Instituto Nacional de Cancer, Brazil
Collaborating Sponsors:
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Conditions:
Breast Cancer
Radio Dermatitis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Most breast cancer patients undergoing radiotherapy develop radiodermatitis, making it one of the most prevalent adverse events during cancer treatment. The severity of radiodermatitis can pose a life...
Detailed Description
This study is a Randomized Controlled Superiority Clinical Trial involving individuals diagnosed with breast cancer and indicated for adjuvant radiotherapy at Hospital do Câncer III of the National Ca...
Eligibility Criteria
Inclusion
- Individuals aged 18 years or older with an indication for adjuvant radiotherapy for breast cancer treatment at National Cancer Institute (INCA-BRAZIL).
Exclusion
- Previous diagnosis of cancer or bilateral breast cancer.
- Oncological treatment outside the institution.
- Connective tissue disorders (such as scleroderma and lupus erythematosus).
- Previous radiotherapy to the breast or chest wall.
- Individuals unable to complete the questionnaires.
- Individuals unable to receive photobiomodulation due to acute infections.
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2029
Estimated Enrollment :
148 Patients enrolled
Trial Details
Trial ID
NCT06990165
Start Date
May 1 2025
End Date
April 1 2029
Last Update
May 25 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute (INCA-BRAZIL)
Rio de Janeiro, Rio de Janeiro, Brazil, 20560-120
2
National Cancer Institute / Cancer Hospital III - Brazil
Rio de Janeiro, Rio de Janeiro, Brazil, 20560-121